Innovative Eyewear, Inc (LUCY) Prices 980K Share Offering at $7.50/sh

Innovative Eyewear, Inc. (NASDAQ: LUCY; LUCYW), a developer and retailer of cutting-edge eyeglasses and sunglasses designed to allow the users to remain connected to their digital lives, today announced the pricing of its initial public offering of 980,000 units consisting of 980,000 shares of its common stock and two accompanying Warrants to purchase up to 1,960,000 shares of common stock. Each share of common stock is being sold together with two Warrants, each to purchase one share of common stock with an exercise price of $7.50 per share at a combined offering price of $7.50, for gross proceeds of approximately $7.35 million, before deducting underwriting discounts and offering expenses. In addition, Innovative Eyewear has granted the underwriters a 45-day option to purchase up to an additional 147,000 shares of common stock and/or Warrants to purchase up to 294,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount. All of the shares of common stock and warrants are being offered by the Company.

The shares of common stock and warrants are expected to begin trading on the Nasdaq Capital Market on August 15, 2022, under the symbols "LUCY" and "LUCYW," respectively. The offering is expected to close on August 17, 2022, subject to satisfaction of customary closing conditions.

The Company intends to use substantially all of the net proceeds from the offering for advancing its sales and marketing, expanding inventory, updating and producing in-store displays, developing new styles and sizes of the Company's smart eyewear, and for working capital and other general corporate purposes.

Maxim Group LLC is acting as the sole book-running manager in connection with the offering.

A registration statement on Form S-1 (File No. 333-261616) was filed with the Securities and Exchange Commission ("SEC"), which became effective on August 12, 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, at (212) 895-3745. Before investing in this offering, interested parties should read in its entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• HCW Biologics prices $1.5M private placement with existing investor
• Waldencast to delist from Nasdaq by early October 2026
• ADARx Pharmaceuticals prices $446.3M IPO at $17 per share